10-Q: Eli Lilly Q1 2026 Earnings Surge on Mounjaro & Zepbound

Eli Lilly reports a significant 56% revenue increase in Q1 2026, driven by strong performance of Mounjaro and Zepbound, alongside substantial net income growth.

Summary

• Eli Lilly reported a substantial increase in revenue for the first quarter of 2026, reaching $19.8 billion, a 56% rise compared to $12.7 billion in the same period of 2025.
• Net income more than doubled, growing by 168% to $7.4 billion from $2.8 billion in Q1 2025.
• Diluted earnings per share saw a significant jump of 170%, reaching $8.26 in Q1 2026 from $3.06 in Q1 2025.
• The growth was primarily fueled by increased volume, particularly from Mounjaro and Zepbound, which together accounted for 65% of total revenue in Q1 2026.
• Research and development expenses increased by 28% to $3.5 billion, reflecting continued investment in the company's pipeline.
• Marketing, selling, and administrative expenses rose by 19% to $2.9 billion, supporting promotional activities for current and upcoming product launches.
• Acquired in-process research and development (IPR&D) charges decreased significantly by 63% to $584 million in Q1 2026 from $1.6 billion in Q1 2025.
• The effective tax rate decreased to 16.4% in Q1 2026 from 20.2% in Q1 2025, partly due to a non-deductible IPR&D charge in the prior year.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a very positive filing, with exceptional revenue and earnings growth driven by blockbuster drugs and promising pipeline developments.

Positives

• Revenue surged by 56% to $19.8 billion in Q1 2026, driven by strong volume growth in key products.
• Net income increased by 168% to $7.4 billion, demonstrating robust profitability.
• Diluted EPS grew by 170% to $8.26, indicating enhanced shareholder value.
• Mounjaro and Zepbound continue to be major growth drivers, with Mounjaro revenue up 125% and Zepbound up 80% year-over-year.
• The company's gross margin remained strong at 81.9% of revenue.
• Significant reduction in acquired IPR&D charges compared to the prior year.
• FDA approval for orforglipron (Foundayo) for obesity treatment in April 2026.
• Phase 3 trials for orforglipron and retatrutide met primary endpoints for type 2 diabetes.
• Initiation of Phase 3 trials for baricitinib (type 1 diabetes), eloralintide (obesity, OSA, OA pain), and brenipatide (major depressive disorder).

Negatives

• Gross margin as a percentage of revenue slightly decreased to 81.9% from 82.5% in the prior year, primarily due to lower realized prices.
• Lower realized prices were observed for Zepbound and Taltz in the U.S., and for Mounjaro outside the U.S. due to factors like China's NRDL inclusion.
• Increased R&D expenses by 28% and SG&A expenses by 19% to support pipeline development and product launches.
• Cash and cash equivalents decreased to $5.3 billion from $7.3 billion, reflecting significant investments and share repurchases.
• Total debt increased to $43.4 billion.
• Ongoing legal proceedings and investigations related to pricing, product liability, and other matters could materially impact results.
• Potential for increased scrutiny and adverse impacts from global tax law changes and increased tax disclosure obligations.

Risks

• Intense competition affecting products and pipeline.
• Market uptake of launched products and indications.
• Continued pricing pressures and actions by governmental and private actors affecting pricing, reimbursement, and patient access.
• Uncertainty surrounding the outcome of voluntary agreements with the U.S. government regarding drug pricing and access.
• Developments or uncertainties related to company or competitive products, including safety or efficacy concerns.
• Dependence on a few products for a significant percentage of total revenue.
• Expiration of intellectual property protection and competition from generic and biosimilar products.
• Ability to protect and enforce patents and other intellectual property.
• Information technology system inadequacies, security breaches, or operating failures.
• Issues with product supply, regulatory approvals, or negative outcomes from manufacturing difficulties or disruptions.
• Reliance on third-party relationships and outsourcing arrangements.
• Use of artificial intelligence and other emerging technologies may exacerbate risks.
• Impact of global macroeconomic conditions, trade disputes, and international tensions.
• Fluctuations in foreign currency exchange rates, interest rates, and inflation/deflation.
• Significant and sudden declines or volatility in stock price and market capitalization.
• Litigation, investigations, or other proceedings involving past, current, or future products, activities, or intellectual property.
• Changes in tax law and regulation, tax rates, or events that differ from tax position assumptions.
• Regulatory changes, developments, and uncertainty, including regulatory oversight and actions.
• Regulatory compliance problems or government investigations.
• Proliferation of counterfeit, misbranded, adulterated, or illegally compounded products.
• Actual or perceived deviation from environmental, social, or governance requirements or expectations.
• Asset impairments and restructuring charges.
• Changes in accounting and reporting standards.

Future Outlook

The company anticipates continued growth driven by its cardiometabolic health products, particularly Mounjaro and Zepbound, and expects these products to remain a significant and growing portion of its business. Near-term financial performance will be influenced by the timing of regulatory approvals for orforglipron, demand, and uptake in new incretin channels and markets. Manufacturing expansion initiatives are underway to support anticipated demand. The company also notes the potential impact of global macroeconomic conditions, trade disputes, and foreign currency fluctuations on its results.

Management Comments

• Revenue increased for the three months ended March 31, 2026, driven primarily by increased volume, partially offset by lower realized prices. The increased volume and lower realized prices during the three months ended March 31, 2026 were primarily driven by Mounjaro and Zepbound.
• Net income and earnings per share for the three months ended March 31, 2026 increased primarily due to higher gross margin and lower acquired IPR&D charges, partially offset by higher research and development expenses and marketing, selling, and administrative expenses.
• Mounjaro and Zepbound accounted for 65 percent of our total revenue for the three months ended March 31, 2026, and we expect cardiometabolic health products will continue to represent a significant and growing portion of our business, revenue, and prospects.
• We continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins. These practices may impact patient safety and undermine regulatory drug approval processes.
• We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements.

Industry Context

StockSavvy.ai notes that Eli Lilly's Q1 2026 results reflect the ongoing dominance of GLP-1 agonists in the obesity and diabetes markets, with Mounjaro and Zepbound driving exceptional growth. This performance aligns with broader industry trends of increasing demand for weight-loss and diabetes treatments, while also highlighting the intense R&D investment required to maintain a competitive edge in this rapidly evolving therapeutic area. The company's strategic acquisitions and pipeline advancements suggest a proactive approach to securing future market share.

Comparison to Industry Standards

• Eli Lilly's revenue growth of 56% in Q1 2026 significantly outpaces the average revenue growth for large pharmaceutical companies, which typically ranges from low to mid-single digits.
• The company's net income growth of 168% is exceptionally high, far exceeding industry norms for established pharmaceutical firms.
• Diluted EPS growth of 170% is also a standout performance, indicating superior operational efficiency and profitability compared to peers.
• The 81.9% gross margin is strong and generally in line with or slightly above the higher end of margins seen in the pharmaceutical sector, which can range from 70% to 85% depending on product mix and R&D capitalization.
• R&D spending as a percentage of revenue (approximately 17.7% in Q1 2026) is substantial and reflects a commitment to innovation, comparable to or higher than many large pharmaceutical companies that invest between 10-20% of revenue in R&D.

Legal Proceedings

• Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. filed a complaint alleging Emgality patent infringement; a jury verdict in favor of Teva was overruled by the trial court, which found patents invalid. The U.S. Court of Appeals for the Federal Circuit reversed and remanded, and Lilly is assessing next steps.
• Ongoing Superfund matters related to environmental cleanup.
• Cosmopolis Facility Labor Attorney Litigation in Brazil: A public civil action alleging harm from alleged exposure to contaminants; a superior labor court significantly reduced a liquidated award, and further appeals are possible.
• 340B Litigation and Investigations: Lawsuit challenging HHS's advisory opinion and ADR regulations regarding discounts to contract pharmacies; appeal pending in the U.S. Court of Appeals for the Seventh Circuit. Other ADR petitions are held in abeyance. Antitrust and unjust enrichment claims related to 340B programs filed by Mosaic Health, Inc. and Central Virginia Health Services, Inc.; petition for U.S. Supreme Court review filed.
• Insulin Pricing Litigation: Numerous lawsuits alleging antitrust, unfair competition, and consumer protection claims related to insulin pricing and rebates. Most cases are coordinated in an MDL in the U.S. District Court for the District of New Jersey. Settlement agreements with New York and Minnesota involved no monetary payments or admission of wrongdoing.
• Insulin and Other Pricing Investigations: Subject to subpoenas and information requests from various governmental entities (DOJ, FTC, state attorneys general) related to pricing of insulin and other diabetes medications.
• Average Manufacturer Price Litigation: A relator filed a qui tam action alleging incorrect calculation of average manufacturer prices; the Seventh Circuit affirmed a jury verdict in favor of the relator, and a petition for U.S. Supreme Court review was filed.
• Actos Litigation: Third-party payer class action alleging concealment of bladder cancer risk; class certification affirmed by the Ninth Circuit.
• Mounjaro, Trulicity, and Zepbound Product Liability Litigation: Lawsuits alleging various injuries from incretin medicines, coordinated in federal MDLs for gastrointestinal injuries and NAION claims. Similar proceedings in state courts and class actions in Israel and Canada.
• Health Choice Alliance: Qui tam lawsuit asserting claims under the Texas Medicaid Fraud Prevention Act related to patient support programs.
• Research Corporation Technologies, Inc.: Lawsuit for breach of contract, unjust enrichment, and conversion related to manufacturing processes; a confidential settlement agreement was reached, with Lilly owing no further payments after a Ninth Circuit reversal.

Stakeholder Impact

• Shareholders: Positive impact due to significant revenue and net income growth, increased EPS, and ongoing share repurchase program.
• Employees: Continued investment in R&D and SG&A suggests ongoing employment opportunities and focus on innovation. Management sales plans under Rule 10b5-1(c) are disclosed.
• Customers: Increased access to obesity medicines through the Medicare Bridge Program and potential for expanded access to other obesity treatments.
• Suppliers: Increased manufacturing expansion initiatives may lead to increased demand for raw materials and services.
• Creditors: Increased total debt to $43.4 billion, but strong cash flow and credit facilities provide comfort.

Next Steps

• Continue to monitor the uptake and demand for Mounjaro and Zepbound in new markets and channels.
• Assess the impact of regulatory approvals for orforglipron (Foundayo) for obesity treatment.
• Continue engagement with the Centers for Medicare & Medicaid Services on long-term Medicare access to obesity medicines.
• Monitor the impact of the Medicare GLP-1 Bridge program and potential expansion of access to obesity medicines.
• Evaluate next steps in the Emgality patent litigation following the U.S. Court of Appeals for the Federal Circuit's opinion.
• Continue to manage ongoing legal proceedings and investigations.
• Implement manufacturing expansion initiatives to support anticipated demand for current and prospective products.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with substantial revenue and net income growth, driven by leading products in high-demand therapeutic areas. Promising clinical trial results and FDA approvals for pipeline candidates indicate strong future growth prospects. Despite ongoing legal and regulatory challenges, the company's financial health, strategic investments, and market position warrant a strong buy recommendation.

Keywords

Eli Lilly, LLY, 10-Q, Quarterly Report, Mounjaro, Zepbound, Orforglipron, Tirzepatide, Obesity, Diabetes, Cardiometabolic Health, Oncology, Immunology, Neuroscience, Pharmaceuticals, Revenue Growth, Net Income, Earnings Per Share, R&D Investment, Acquisitions, Ventyx Biosciences, Verve Therapeutics, Clinical Trials, FDA Approval, Drug Pricing, Inflation Reduction Act